Shots:

• The company launch Yuflyma (adalimumab-aaty) for the treatment of 8 conditions: RA, JIA, PsA, AS, CD, UC, PsO, and HS. Yuflyma is a high-concentration (100mg/mL) & a citrate-free adalimumab biosimilar
• The biosimilar is available in auto-injector and prefilled syringe options. Yuflyma became commercially available among key distributors across the US & has a longer shelf life than Humira maintaining stability at 25℃ (77°F) for 30 days, and is administered via a latex-free device.
• Additionally. the company also provided the patient support program Celltrion CONNECT along with Celltrion CARES Co-pay Assistance Program that will commence on July 10

Ref: Businesswire | Image: Celltrion

Related News:- Celltrion’s Yuflyma (biosimilar, adalimumab) Receives the US FDA’s Approval for Multiple Indications

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com